Telesis Bio INC

Telesis Bio Inc. has entered into promissory notes with Novalis LifeSciences Investments II, L.P. and Northpond Ventures III, LP, securing $3 million in debt financing.

Telesis Bio Inc. has announced the departure of its Chief Legal Officer, Robert H. Cutler, effective October 31, 2024, and detailed the terms of his separation agreement.

Telesis Bio has announced its decision to delist from the Nasdaq Global Select Market due to its inability to meet minimum listing requirements.

Telesis Bio Inc. reports the immediate resignation of five board members and subsequent appointment of new committee members, including the CEO as board chair.

Telesis Bio Inc. has finalized the sale of its wholly-owned subsidiary, EtonBio, Inc., to Yuan (Terry) Yang, as of August 26, 2024.

Telesis Bio Inc. has agreed to sell its wholly-owned subsidiary, Eton Bio, Inc., to Yuan (Terry) Yang for $1.5 million, pending customary closing conditions.

Telesis Bio Inc. reports a net loss of $6.6 million for the third quarter of 2024, alongside the sale of its Eton subsidiary and a shift to the OTC Pink market.

Telesis Bio's Q2 2024 results reflect a period of strategic transition, including the divestiture of EtonBio, and financial restructuring efforts.

Telesis Bio's first quarter 2024 results show a decrease in revenue compared to the same period last year, alongside reduced operating expenses and a net loss of $8.6 million.

Telesis Bio Inc. issues a warrant to MidCap Financial Trust as part of a debt restructuring agreement, while also disclosing concerns about its ability to continue as a going concern.

Director Todd Krueger acquired 8,390 restricted stock units and options to purchase 5,268 shares of Telesis Bio Inc. common stock on July 24, 2024.

Director Steven J. Golub acquired 8,390 shares of common stock and 5,268 stock options in Telesis Bio Inc. on July 24, 2024.

Director Sarah E. Hlavinka reports acquisition of Telesis Bio Inc. stock and options on July 24, 2024.

Director Michael R. Hodges acquired shares and options in Telesis Bio Inc. on July 24, 2024, through restricted stock units (RSUs) and stock options.

Director James B. Weissman acquired 8,390 shares of common stock and 5,268 stock options in Telesis Bio Inc. on July 24, 2024.

Director Frank Witney reports acquisition and disposal of Telesis Bio Inc. stock and stock options.

Telesis Bio is holding its 2024 Annual Meeting of Stockholders virtually on May 1, 2024, to vote on director elections, a reverse stock split, and the ratification of its independent accounting firm.